The FDA approved Genentech’s Wilserdly (giredestrant) in combination with everolimus for adults with advanced breast cancer whose ESR1 mutations were confirmed by an authorized test. In the evERA trial, median progression-free survival was 10.0 months in patients with ESR1 mutations, compared with 5.5 months in the control group, representing a 62% reduction in the risk of disease progression. However, the confidence interval for the hazard ratio for death reached or crossed 1.0, and an overall survival benefit has not yet been demonstrated. The labeled dose is 30 mg once daily, and an FDA-authorized ESR1 test is required.
Source:Tech Times · Read Original
Leave a Reply